Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Single-Cell Analysis Based Dissection of Clonality in Myelofibrosis

Blood (2019) 134 (Supplement_1): 469.

https://doi.org/10.1182/blood-2019-123367

Published: 2019

Journal Articles

Transcriptional Profiling Reveals Strong Impact of Major Molecular Disease Subgroups and Mixed Epistasis in Chronic Lymphocytic Leukemia

Thorsten Zenz, MD, Almut Luetge, Junyan Lu, PhD, Huellein Jennifer, PhD, Sascha Dietrich, MD, Leopold Sellner, MD, Wolfgang Huber, PhD

Blood (2019) 134 (Supplement_1): 1742.

https://doi.org/10.1182/blood-2019-126388

Published: 2019

Journal Articles

Igcaller: Reconstructing the Rearranged Immunoglobulin Gene in Lymphoid Neoplasms from Whole-Genome Sequencing Data

Ferran Nadeu, Rut Mas-de-les-Valls, Romina Royo, Alba Navarro, Sílvia Beà, Junyan Lu, PhD, Alfredo Rivas-Delgado, MD, Neus Villamor, Silvia Martín, Marta Aymerich, Tycho Baumann, Julio Delgado, Dolors Colomer, PhD, Xose S Puente, Thorsten Zenz, MD, Peter J Campbell, Francesco Maura, MD, Elias Campo

Blood (2019) 134 (Supplement_1): 3023.

https://doi.org/10.1182/blood-2019-130071

Published: 2019

Journal Articles

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

Nora Liebers, Peter-Martin Bruch, Agnes Gambietz, Holly Giles, BA, Junyan Lu, PhD, Mareike Knoll, Carolin Kolb, Peter Dreger, Carsten Mueller-Tidow, MD, Wolfgang Huber, PhD, Axel Benner, Thorsten Zenz, MD, Sascha Dietrich, MD

Blood (2019) 134 (Supplement_1): 376.

https://doi.org/10.1182/blood-2019-125324

Published: 2019

Journal Articles

Systematic Investigation of Microenvironmental Drug Resistance Mechanisms in Chronic Lymphocytic Leukemia

Peter-Martin Bruch, Holly Giles, BA, Carolin Kolb, Sophie Rabe, MSc, Tobias Roider, MD, Mareike Knoll, Mark Kriegsmann, MD, Katharina Kriegsmann, MD, Christiane Zgorzelski, Sebastian Scheinost, Lena Wagner, Carsten Müller-Tidow, MD, Thorsten Zenz, MD, Wolfgang Huber, PhD, Sascha Dietrich, MD

Blood (2019) 134 (Supplement_1): 3363.

https://doi.org/10.1182/blood-2019-128392

Published: 2019

Journal Articles

The U1 Spliceosomal RNA: A Novel Non-Coding Hotspot Driver Mutation Independently Associated with Clinical Outcome in Chronic Lymphocytic Leukemia

Blood (2019) 134 (Supplement_1): 847.

https://doi.org/10.1182/blood-2019-130052

Published: 2019

Journal Articles

Modeling of the Epigenome of the Cell-of-Origin Identifies Cancer-Specific DNA Methylation Patterns in CLL

Justyna Anna Wierzbinska, Reka Toth, Naveed Ishaque, Jan-Phillip Mallm, Karsten Rippe, Daniel Mertens, Thomas Hielscher, Thorsten Zenz, MD, Marc Seifert, Ralf Küppers, Yassen Assenov, Stephan Stilgenbauer, John C. Byrd, MD, Christopher C. Oakes, Daniel B. Lipka, Christoph Plass

Blood (2018) 132 (Supplement 1): 3885.

https://doi.org/10.1182/blood-2018-99-115941

Published: 2018

Journal Articles

The Influence of the Bone Marrow Niche on Drug Response Phenotypes of Blood Cancers

Sophie Rabe, MSc, Eva Schitter, Tobias Roider, Peter-Martin Bruch, Carolin Kolb, Marta Stolarczyk, Jennifer Hüllein, Junyan Lu, Christof von Kalle, Christoph Lutz, Peter Dreger, Carsten Mueller-Tidow, Thorsten Zenz, MD, Wolfgang Huber, Sascha Dietrich, MD

Blood (2018) 132 (Supplement 1): 262.

https://doi.org/10.1182/blood-2018-99-116053

Published: 2018

Journal Articles

Recurrent Mutations in EGR2 Direct Specific Epigenetic Reconfiguration in Chronic Lymphocytic Leukemia

Blood (2018) 132 (Supplement 1): 650.

https://doi.org/10.1182/blood-2018-99-119070

Published: 2018

Journal Articles

Genetic Characterization of B-Cell Prolymphocytic Leukemia (B-PLL): A Hierarchical Prognostic Model Involving MYC and TP53 Abnormalities. on Behalf of the Groupe Francophone De Cytogenetique Hematologique (GFCH) and the French Innovative Leukemia Organization (FILO) Group

Blood (2018) 132 (Supplement 1): 943.

https://doi.org/10.1182/blood-2018-99-115085

Published: 2018

Journal Articles

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

Fie Juhl Vojdeman, MD, Lone Bredo Pedersen, Doreen Te Raa, MD PhD, Vesa Juvonen, PhD, Yvette Norden, Geir Erland Tjønnfjord, MD DMsc, Eva Kimby, Maija Itälä-Remes, MD PhD, Anton W Langerak, Ludo M. Evers, Thorsten Zenz, MD, Marinus H.J. Van Oers, MD PhD, Christian H. Geisler, MD PhD, Arnon P. Kater, MD, Carsten Utoft Niemann, MD PhD

Blood (2017) 130 (Supplement 1): 4312.

https://doi.org/10.1182/blood.V130.Suppl_1.4312.4312

Published: 2017

Journal Articles

Genomic Analysis of Hairy Cell Leukemia Identifies Novel Recurrent Genetic Alterations

Blood (2017) 130 (Supplement 1): 2994.

https://doi.org/10.1182/blood.V130.Suppl_1.2994.2994

Published: 2017

Journal Articles

IL-10 Production By CLL Cells Is Enhanced in the Anergic IGHV Mutated Subset and Associates with Reduced DNA Methylation of the IL-10 Locus

Samantha Drennan, PhD, Annalisa D'Avola, MSc, Yifang Gao, PhD, Eleni Chrysostomou, MSc, Andrew J Steele, PhD, Thorsten Zenz, MD, Christoph Plass, PhD, Peter W Johnson, MD, Anthony P Williams, PhD FRCPath, Graham Packham, PhD, Freda K Stevenson, DPhil, Christopher C. Oakes, PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2015) 126 (23): 2917.

https://doi.org/10.1182/blood.V126.23.2917.2917

Published: 2015

Journal Articles

Assessment of p53 and ATM Functionality in Chronic Lymphocytic Leukemia By Multiplex Ligation-Dependent Probe Amplification

Doreen te Raa, Perry Moerland, Alexander Leeksma, Ingrid Derks, Martin Loden, Veronika Navrkalova, Martin Trbusek, PhD, Dieuwertje Luijks, Thorsten Zenz, MD, Anna Skowronska, PhD, Tatjana Stankovic, Mels Hoogendoorn, MD PhD, Marinus H. J. van Oers, Eric Eldering, PhD, Arnon P. Kater, MD PhD

Blood (2015) 126 (23): 2918.

https://doi.org/10.1182/blood.V126.23.2918.2918

Published: 2015

Journal Articles

T-Prolymphocytic Leukemia Is Sensitive to Polyclonal T Cell-Derived Graft-Versus-Leukemia Effects: Evidence from Minimal Residual Disease Kinetics and TCR Repertoire Diversity Analyses

Leopold Sellner, MD, Peter Dreger, MD, Max Schlitt, Henrik Knecht, Dietrich Herrmann, Thomas Reigl, Adam Krejci, Vojtech Bystry, Nikos Darzentas, Michael Rieger, MD, Sascha Dietrich, MD, Thorsten Zenz, MD, Anthony D. Ho, MD, Michael Kneba, Monika Brueggemann

Blood (2015) 126 (23): 3159.

https://doi.org/10.1182/blood.V126.23.3159.3159

Published: 2015

Journal Articles

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Shady Adnan, MD MSc, Leopold Sellner, MD, Dorine Bellanger, Alexandra Schrader, Giuliano Crispatzu, Henan Zhang, MD, Carlos C Mateos, PhD, Edgar Faber, MD PhD, Steffen Koschmieder, MD, Tim H. Brummendorf, MD PhD, Krister Wennerberg, PhD, Wei Ding, MD PhD, Marc-Henri Stern, MD PhD, Marco Herling, MD, Simon Anders, PhD, Wolfgang Huber, PhD, Thorsten Zenz, MD, Satu Mustjoki, MD, PhD

Blood (2015) 126 (23): 315.

https://doi.org/10.1182/blood.V126.23.315.315

Published: 2015

Journal Articles

Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in “ultra High-risk” CLL: Final Results from the CLL2O Phase II Study

Blood (2014) 124 (21): 1991.

https://doi.org/10.1182/blood.V124.21.1991.1991

Published: 2014

Journal Articles

Induction Treatment with Alemtuzumab Combined with Polychemotherapy Containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Followed By Alemtuzumab Maintenance in Patients with T-Cell Prolymphocytic Leukaemia (T-PLL): First Analysis of a Prospective Multicenter Phase-II-Trial (T-PLL2) Conducted By the German CLL Study Group (GCLLSG)

Natali Pflug, MD, Georg Hopfinger, MD, Paula Cramer, MD, Alexandra Schrader, PhD, Nicole Weit, PhD, Rita Meister, Miriam Thiel, Tanja Annolleck, Anne Westermann, Till M Seiler, MD, Thorsten Zenz, MD, Jan Duerig, MD, Jasmin Bahlo, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD, Anna-Maria Fink, MD, Barbara Eichhorst, MD, Michael Hallek, MD, Marco Herling, MD

Blood (2014) 124 (21): 1999.

https://doi.org/10.1182/blood.V124.21.1999.1999

Published: 2014

Journal Articles

High-Resolution Genomic Copy Number Analysis on Sequential Samples from the CLL8 Trial: Relation Between Clonal Evolution and Defects in DNA Damage Response?

Jennifer Edelmann, MD, Eugen Tausch, MD, Johannes Bloehdorn, MD, Thorsten Zenz, MD, Kirsten Fischer, MD, Jasmin Bahlo, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 1964.

https://doi.org/10.1182/blood.V124.21.1964.1964

Published: 2014

Journal Articles

The Flavonoid Wogonin Reduces CLL Cell Survival in Vitro and Leukemia Development in Eµ-TCL1 Mice By Targeting Aberrant TNF Receptor Signaling

Claudia Dürr, Bola Hanna, Fabienne McClanahan, MD, Andrew James Clear, BSc, Thorsten Zenz, MD, Stephan Stilgenbauer, MD, John G. Gribben, MD DSc, Peter Lichter, PhD, Martina Seiffert, PhD

Blood (2014) 124 (21): 1966.

https://doi.org/10.1182/blood.V124.21.1966.1966

Published: 2014

NARROW

Single-Cell Analysis Based Dissection of Clonality in Myelofibrosis

Transcriptional Profiling Reveals Strong Impact of Major Molecular Disease Subgroups and Mixed Epistasis in Chronic Lymphocytic Leukemia

Igcaller: Reconstructing the Rearranged Immunoglobulin Gene in Lymphoid Neoplasms from Whole-Genome Sequencing Data

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

Systematic Investigation of Microenvironmental Drug Resistance Mechanisms in Chronic Lymphocytic Leukemia

The U1 Spliceosomal RNA: A Novel Non-Coding Hotspot Driver Mutation Independently Associated with Clinical Outcome in Chronic Lymphocytic Leukemia

Modeling of the Epigenome of the Cell-of-Origin Identifies Cancer-Specific DNA Methylation Patterns in CLL

The Influence of the Bone Marrow Niche on Drug Response Phenotypes of Blood Cancers

Recurrent Mutations in EGR2 Direct Specific Epigenetic Reconfiguration in Chronic Lymphocytic Leukemia

Genetic Characterization of B-Cell Prolymphocytic Leukemia (B-PLL): A Hierarchical Prognostic Model Involving MYC and TP53 Abnormalities. on Behalf of the Groupe Francophone De Cytogenetique Hematologique (GFCH) and the French Innovative Leukemia Organization (FILO) Group

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

Genomic Analysis of Hairy Cell Leukemia Identifies Novel Recurrent Genetic Alterations

IL-10 Production By CLL Cells Is Enhanced in the Anergic IGHV Mutated Subset and Associates with Reduced DNA Methylation of the IL-10 Locus

Assessment of p53 and ATM Functionality in Chronic Lymphocytic Leukemia By Multiplex Ligation-Dependent Probe Amplification

T-Prolymphocytic Leukemia Is Sensitive to Polyclonal T Cell-Derived Graft-Versus-Leukemia Effects: Evidence from Minimal Residual Disease Kinetics and TCR Repertoire Diversity Analyses

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in “ultra High-risk” CLL: Final Results from the CLL2O Phase II Study

High-Resolution Genomic Copy Number Analysis on Sequential Samples from the CLL8 Trial: Relation Between Clonal Evolution and Defects in DNA Damage Response?

The Flavonoid Wogonin Reduces CLL Cell Survival in Vitro and Leukemia Development in Eµ-TCL1 Mice By Targeting Aberrant TNF Receptor Signaling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only